SCHEMBL4061121

SCHEMBL4061121

Pc1cccc(-c2ccccc2-c2ccccc2)c1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 1/20 0.39
ALDH1A1 P00352 6/20 0.39
HSD17B10 Q99714 2/20 0.39
HPGD P15428 1/20 0.39
BCL2L1 Q07817 1/20 0.39
CYP2A6 P11509 1/20 0.39
MAPK1 P28482 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 1/20 0.37
PTGS2 P35354 1/20 0.36
BACE1 P56817 1/20 0.36
DPP4 P27487 1/20 0.35
PDCD1 Q15116 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
ENPP1 P22413 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30114855 0.91 ALDH1A1 (0.42) HNF4AALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL288550 0.91 ALDH1A1 (0.42) HNF4AALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL8393810 0.88 ALDH1A1 (0.41) HNF4AALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL31276160 0.83 ALDH1A1 (0.44) HNF4AALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL30332623 0.83 ALDH1A1 (0.44) HNF4AALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL30332908 0.83 ALDH1A1 (0.44) HNF4AALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL14878584 0.83 ALDH1A1 (0.44) ALDH1A1HSD17B10HPGDBCL2L1CYP2A6
SCHEMBL30355086 0.80 ALDH1A1 (0.46) HNF4AALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL27637312 0.78 ALDH1A1 (0.46) HNF4AALDH1A1HSD17B10HPGDBCL2L1
SCHEMBL5375695 0.78 ALDH1A1 (0.44) HNF4AALDH1A1HSD17B10HPGDBCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0531256-B1 Method for preparing glycosides CIBA GEIGY AG (CH) 1997-04-23 EP claimed
US-5342929-A Direct glycosylation leads to the desired glycosides in high yield and relatively short reaction times using metal complex salts; large amounts of the alpha- or beta-form are often obtained CIBA-GEIGY CORPORATION (US) 1994-08-30 US claimed
US-12415835-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-16 US disclosed
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-23 US disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 US disclosed
EP-3974563-A1 CYCLIC PEPTIDES Chugai Seiyaku Kabushiki Kaisha (JP) 2022-03-30 EP disclosed
EP-2813512-B1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI PHARMACEUTICAL CO LTD (JP) 2021-03-31 EP disclosed
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-03-04 US disclosed
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-10-27 US disclosed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 US disclosed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 US disclosed
EP-2813512-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD Chugai Seiyaku Kabushiki Kaisha (JP) 2014-12-17 EP disclosed
WO-2009123675-A1 IMPROVED CARBONYLATION PROCESS EASTMAN CHEMICAL COMPANY (US) 2009-10-08 WO disclosed
US-20090247783-A1 CARBONYLATION PROCESS EASTMAN CHEMICAL COMPANY (US) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R HNF4A 2906/4885ALDH1A1 4857/4885HSD17B10 3115/4885
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R HNF4A 2906/4885ALDH1A1 4857/4885HSD17B10 3115/4885
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R HNF4A 2906/4885ALDH1A1 4857/4885HSD17B10 3115/4885
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R HNF4A 2906/4885ALDH1A1 4857/4885HSD17B10 3115/4885
US-20090247783-A1 CARBONYLATION PROCESS CA4, HAO2, CA9 HNF4A 313/4885ALDH1A1 805/4885HSD17B10 1123/4885
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R HNF4A 2906/4885ALDH1A1 4857/4885HSD17B10 3115/4885
US-12415835-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R HNF4A 2906/4885ALDH1A1 4857/4885HSD17B10 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.